Literature DB >> 30524901

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Jonathan G Pol1,2,3,4,5, Sarah Lévesque1,2,3,4,5, Samuel T Workenhe6,7,8, Shashi Gujar9,10,11,12, Fabrice Le Boeuf13,14, Derek R Clements9, Jean-Eudes Fahrner1,15,16, Laetitia Fend16, John C Bell13,14, Karen L Mossman6,7,8, Jitka Fucikova17,18, Radek Spisek17,18, Laurence Zitvogel1,15, Guido Kroemer1,2,3,4,5,19,20,21, Lorenzo Galluzzi4,22,23.   

Abstract

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Entities:  

Keywords:  CAVATAK; DNX-2401; HF10; MV-NIS; Maraba MG1; Pexa-Vec; REOLYSIN; T-VEC

Year:  2018        PMID： 30524901      PMCID： PMC6279343          DOI： 10.1080/2162402X.2018.1503032

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  343 in total

1.  Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.

Authors:  Kenneth N Barton; Dell Paielli; Yingshu Zhang; Sweaty Koul; Stephen L Brown; Mei Lu; John Seely; Jae Ho Kim; Svend O Freytag
Journal:  Mol Ther       Date:  2005-11-14       Impact factor: 11.454

2.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus.

Authors:  Yuuri Hashimoto; Yuichi Watanabe; Yoshiko Shirakiya; Futoshi Uno; Shunsuke Kagawa; Hitoshi Kawamura; Katsuyuki Nagai; Noriaki Tanaka; Horomi Kumon; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Cancer Sci       Date:  2008-01-14       Impact factor: 6.716

Review 4.  Oncolytic viruses: a novel form of immunotherapy.

Authors:  Robin J Prestwich; Kevin J Harrington; Hardev S Pandha; Richard G Vile; Alan A Melcher; Fiona Errington
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

5.  Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.

Authors:  Svend O Freytag; Kenneth N Barton; Stephen L Brown; Vinod Narra; Yingshu Zhang; Don Tyson; Colleen Nall; Mei Lu; Munther Ajlouni; Benjamin Movsas; Jae Ho Kim
Journal:  Mol Ther       Date:  2007-06-12       Impact factor: 11.454

6.  Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.

Authors:  Tanja I Näslund; Catherine Uyttenhove; Eva K L Nordström; Didier Colau; Guy Warnier; Mikael Jondal; Benoît J Van den Eynde; Peter Liljeström
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

7.  Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.

Authors:  Ilya V Ulasov; Zeng B Zhu; Matthew A Tyler; Yu Han; Angel A Rivera; Andrey Khramtsov; David T Curiel; Maciej S Lesniak
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

Review 8.  Oncolytic herpes simplex virus vectors for cancer virotherapy.

Authors:  Susan Varghese; Samuel D Rabkin
Journal:  Cancer Gene Ther       Date:  2002-12       Impact factor: 5.987

9.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

10.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.

Authors:  Paulo C Rodriguez; Claudia P Hernandez; David Quiceno; Steven M Dubinett; Jovanny Zabaleta; Juan B Ochoa; Jill Gilbert; Augusto C Ochoa
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307
View more
  31 in total

1.  Role of heat-shock proteins in infection of human adenocarcinoma cell line MCF-7 by tumor-adapted rotavirus isolates.

Authors:  Claudia Perez; José Rico; Carlos Guerrero; Orlando Acosta
Journal:  Colomb Med (Cali)       Date:  2021-03-16

2.  Chitosan-Based Delivery of Avian Reovirus Fusogenic Protein p10 Gene: In Vitro and In Vivo Studies towards a New Vaccine against Melanoma.

Authors:  Claudia Robles-Planells; Carlos Barrera-Avalos; Leonel E Rojo; Eugenio Spencer; Marcelo Cortez-San Martin; Silvia Matiacevich; Jorge Pavez; Luis A Milla; Franco D Navarro; Brandon A Martínez; Francisco J Bravo; Andrea Mella; Juan Pablo Huidobro-Toro; Ricardo Fernandez; Alejandro Escobar; Claudio Acuña Castillo
Journal:  Biomed Res Int       Date:  2020-06-13       Impact factor: 3.411

Review 3.  Engineering and combining oncolytic measles virus for cancer therapy.

Authors:  Mathias F Leber; Serge Neault; Elise Jirovec; Russell Barkley; Aida Said; John C Bell; Guy Ungerechts
Journal:  Cytokine Growth Factor Rev       Date:  2020-07-03       Impact factor: 7.638

Review 4.  Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?

Authors:  Maria Eugenia Davola; Karen Louise Mossman
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

5.  A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.

Authors:  Sarah Lévesque; Julie Le Naour; Federico Pietrocola; Juliette Paillet; Margerie Kremer; Francesca Castoldi; Elisa E Baracco; Yan Wang; Erika Vacchelli; Gautier Stoll; Ariane Jolly; Pierre De La Grange; Laurence Zitvogel; Guido Kroemer; Jonathan G Pol
Journal:  Oncoimmunology       Date:  2019-09-07       Impact factor: 8.110

Review 6.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

7.  MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.

Authors:  Hans Martin Singh; Mathias Felix Leber; Sascha Bossow; Christine E Engeland; Jan Dessila; Christian Grossardt; Karim Zaoui; John C Bell; Dirk Jäger; Christof von Kalle; Guy Ungerechts
Journal:  Mol Ther Oncolytics       Date:  2021-05-05       Impact factor: 7.200

8.  Chitosan-Based Nanoparticles for Intracellular Delivery of ISAV Fusion Protein cDNA into Melanoma Cells: A Path to Develop Oncolytic Anticancer Therapies.

Authors:  Claudia Robles-Planells; Giselle Sánchez-Guerrero; Carlos Barrera-Avalos; Silvia Matiacevich; Leonel E Rojo; Jorge Pavez; Edison Salas-Huenuleo; Marcelo J Kogan; Alejandro Escobar; Luis A Milla; Ricardo Fernandez; Mónica Imarai; Eugenio Spencer; Juan Pablo Huidobro-Toro; Claudio Acuña-Castillo
Journal:  Mediators Inflamm       Date:  2020-04-29       Impact factor: 4.711

Review 9.  Calreticulin and cancer.

Authors:  Jitka Fucikova; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Res       Date:  2020-07-30       Impact factor: 25.617

Review 10.  Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Authors:  Yogesh R Suryawanshi; Autumn J Schulze
Journal:  Viruses       Date:  2021-07-02       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.